A prespecified analysis of the TAILORx randomised trial applied an AI model reading H&E pathology slides alongside clinical variables to 6,735 node-negative, hormone receptor-positive breast cancer patients, with no TAILORx data used in training. The score was associated with disease-free interval in both treatment arms and remained significant after adjustment for the 21-gene Recurrence Score, and within the intermediate-risk group it identified a chemotherapy benefit (5 percentage points higher 5-year disease-free interval) that the genomic assay itself did not detect (interaction p=0.001 for the AI score against p=0.20 for the genomic score).
Why it is interesting: An externally validated, prespecified test of image-based AI as a predictive rather than merely prognostic marker, in a randomised trial where the genomic assay itself found no such interaction.